John C. Chan

John C. Chan

Oncology | Obstetrics and Gynecology

1100 Van Ness Ave
4th Fl
San Francisco, CA 94109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 233 publications

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal: JCO precision oncology

Published: July 15, 2026

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Journal: Gynecologic oncology

Published: June 14, 2026

Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal: JCO precision oncology

Published: April 30, 2026

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal: JCO precision oncology

Published: April 30, 2026

Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Journal: JCO precision oncology

Published: April 22, 2026

Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.

Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.

Journal: Gynecologic oncology

Published: April 12, 2026

Evidence of Higgs Boson Inclusive Production at High Transverse Momentum Decaying to a Pair of b-Quarks with the ATLAS Detector.

Evidence of Higgs Boson Inclusive Production at High Transverse Momentum Decaying to a Pair of b-Quarks with the ATLAS Detector.

Journal: Physical review letters

Published: March 24, 2026

Combination of Measurements of CP Properties of Higgs Boson Interactions with Vector Bosons Using Proton-Proton Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Combination of Measurements of CP Properties of Higgs Boson Interactions with Vector Bosons Using Proton-Proton Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Journal: Physical review letters

Published: March 24, 2026

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Journal: Gynecologic oncology

Published: March 04, 2026

Variations and patterns in germline and somatic testing by age in ovarian, primary peritoneal, and fallopian tube cancer patients: a descriptive analysis in a large, real-world clinical and genetic data registry.

Variations and patterns in germline and somatic testing by age in ovarian, primary peritoneal, and fallopian tube cancer patients: a descriptive analysis in a large, real-world clinical and genetic data registry.

Journal: Gynecologic oncology reports

Published: March 03, 2026

The Impact of Climate Vulnerability on Cancer Incidence Among U.S. Women.

The Impact of Climate Vulnerability on Cancer Incidence Among U.S. Women.

Journal: Cureus

Published: January 28, 2026

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

Journal: Journal for immunotherapy of cancer

Published: January 20, 2026

Showing 1-12 of 233

Last Updated: 09/26/2026